Abstract
Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporally related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of ~10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo- controlled trials are needed to more fully evaluate the utility of famoditine in the treatment of schizophrenia.
Original language | English (US) |
---|---|
Pages (from-to) | 369-374 |
Number of pages | 6 |
Journal | Clinical neuropharmacology |
Volume | 18 |
Issue number | 4 |
DOIs | |
State | Published - Jan 1 1995 |
Externally published | Yes |
Keywords
- Famotidine
- H2 antagonist
- H2 receptor
- Histamine
- Schizophrenia
ASJC Scopus subject areas
- Pharmacology
- Clinical Neurology
- Pharmacology (medical)